MRC1 and prostate carcinoma: LNCap prostate cancer cells respond to a bicalutamide challenge by upregulating expression of error-prone DNA polymerases and downregulating expression of high-fidelity DNA polymerases and mismatch repair (MMR) proteins, resulting in an increased mutation rate [16].